Singapore Pharmaceuticals and Healthcare Report Q2 2014

Date: March 12, 2014
Pages: 129
US$ 1,295.00
Publisher: Business Monitor International
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Includes 3 FREE quarterly updates

BMI View: Abbvie's latest investment into Singapore highlights the country's strength as a biotechnology hub for multinational pharmaceutical firms. In addition to the country's expertise, the ageing population coupled with the government's promise to improve healthcare affordability are other growth opportunities for pharmaceutical firms. However, its long-term growth potential will continue to be limited by its small population.

Headline Expenditure Projections
  • Pharmaceuticals: SGD990mn (US$790mn) in 2013 to SGD1.04bn (US$840mn) in 2014; +5.5% in local currency terms and +6.3% in US dollar terms.
  • Healthcare: SGD17.77bn (US$14.20bn) in 2013 to SGD19.66bn (US$15.83bn) in 2014; +10.6% in local currency terms and +11.5% in US dollar terms.
BMI Industry View
Business Environment
Industry Forecast
Pharmaceutical Market Forecast
  Table: Pharmaceutical Sales Indicators 2010-2018
Healthcare Market Forecast
  Table: Healthcare Expenditure Indicators, 2010-2018
  Table: Healthcare Governmental Indicators, 2010-2018.
  Table: Healthcare Private Indicators, 2010-2018.
Prescription Drug Market Forecast
  Table: Prescription Drug Sales Indicators, 2010-2018
Patented Drug Market Forecast
  Table: Patented Drug Market Indicators, 2010-2018.
Generic Drug Market Forecast
  Table: Generic Drug Sales Indicators, 2010-2018
OTC Medicine Market Forecast
  Table: OTC Medicine Sales Indicators, 2010-2018
Pharmaceutical Trade Forecast
  Table: Singapore Pharmaceutical Trade Data And Forecasts (SGDmn).
Other Healthcare Data
Key Risks To BMI's Forecast Scenario
Macroeconomic Forecasts
Services Still Vulnerable To External Conditions
Export Picture Only Slightly Better For 2014
Domestic Economic Fundamentals Remain Sound
Household Debt A Risk
  Table: Singapore - Economic Activity.
Industry Risk Reward Ratings
Asia Risk/Reward Ratings
Singapore Risk/Reward Ratings
Market Overview
Industry Trends And Developments
  Table: Top Causes Of Death In Singapore, 2010-2012
Healthcare Sector
  Table: Health Funding Sources In Singapore (SGDmn)
Healthcare Insurance
Healthcare Company Developments
Medical Tourism
International Healthcare Collaboration
Research & Development
Bioscience Sector
Research & Development Activity
Clinical Trials
Regulatory Development
Regional Harmonisation
Intellectual Property Issues
Trade Agreements
Pricing And Reimbursement Regime
Competitive Landscape
Pharmaceutical Industry
  Table: Pharmaceutical Manufacturing In Singapore, 2004-2012
  Table: Singapore's Leading Healthcare And Pharmaceutical Companies According To Market Capitalisation (US$mn)
Domestic Pharmaceutical Sector
Foreign Industry
  Table: Multinational Pharmaceutical Firms' Presence In Singapore.
Traditional Chinese Medicine
Pharmaceutical Distribution
Pharmaceutical Wholesaling
Pharmaceutical Retail Sector
Company Profile
Haw Par
Sci Gen
Veredus Laboratories
Merck & Co
Demographic Forecast
Demographic Outlook
  Table: Singapore's Population By Age Group, 1990-2020 ('000)
  Table: Singapore's Population By Age Group, 1990-2020 (% of total)
  Table: Singapore's Key Population Ratios, 1990-2020
  Table: Singapore's Rural And Urban Population, 1990-2020
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Ratings Methodology
Ratings Overview
  Table: Pharmaceutical Risk/Reward Ratings Indicators.
Indicator Weightings

Ask Your Question

Singapore Pharmaceuticals and Healthcare Report Q2 2014
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: